Abstract
Triazoloacridinones (TA) are a class of antitumor agents including a new compound C-1305 now in preclinical trials. In this study, the ability of triazoloacridinones to DNA minor groove binding and relevance to biological activity was investigated, using fluorochrome displacement method. From selected seven triazoloacridinone derivatives, differing in chemical structures, as well as in cytotoxic and antitumour activities only four of them showed C50 parameters (stronger DNA-binders in the minor groove). Weak or lack of correlation between minor groove binding and cytotoxic activities, suggested that these modes of interaction do not play a major role in the mechanism of biological action of TA.
Keywords: Triazoloacridinones, Antitumor compounds, Minor groove binding, Intercalation, Mechanism of biological action
Letters in Drug Design & Discovery
Title: Is DNA Minor Groove Binding Crucial for Biological Activity of Triazoloacridinones with Cytotoxic and Antitumour Properties?
Volume: 6 Issue: 4
Author(s): Marcin Koba, Katarzyna Koba and Tomasz Baczek
Affiliation:
Keywords: Triazoloacridinones, Antitumor compounds, Minor groove binding, Intercalation, Mechanism of biological action
Abstract: Triazoloacridinones (TA) are a class of antitumor agents including a new compound C-1305 now in preclinical trials. In this study, the ability of triazoloacridinones to DNA minor groove binding and relevance to biological activity was investigated, using fluorochrome displacement method. From selected seven triazoloacridinone derivatives, differing in chemical structures, as well as in cytotoxic and antitumour activities only four of them showed C50 parameters (stronger DNA-binders in the minor groove). Weak or lack of correlation between minor groove binding and cytotoxic activities, suggested that these modes of interaction do not play a major role in the mechanism of biological action of TA.
Export Options
About this article
Cite this article as:
Koba Marcin, Koba Katarzyna and Baczek Tomasz, Is DNA Minor Groove Binding Crucial for Biological Activity of Triazoloacridinones with Cytotoxic and Antitumour Properties?, Letters in Drug Design & Discovery 2009; 6 (4) . https://dx.doi.org/10.2174/157018009788452465
DOI https://dx.doi.org/10.2174/157018009788452465 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors
Drug Metabolism Letters Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion Proteins
Current Pharmaceutical Design The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design